changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
London, UK, 08 January 2015
BTG plc (LSE: BTG), the specialist healthcare company, announced on 4 December 2014 that it had entered into an agreement to buy PneumRx Inc, a growing interventional pulmonology business, conditional on the expiration or early termination of the waiting period under the Hart-Scott-Rodino Act in the US.
BTG is pleased to announce that the parties received early termination of the waiting period and the acquisition completed on Wednesday 7 January 2015.
BTG FTI Consulting
Andy Burrows, VP, Corporate & Investor Relations Ben Atwell/Simon Conway
+44 (0)20 7575 1741; Mobile: +44 (0)7990 530605 +44 (0)20 3727 1000
Stuart Hunt, Investor Relations Manager
+44 (0)20 7575 1582; Mobile: +44 (0)7815 778 536
BTG is an international specialist healthcare company that is developing and commercializing products targeting acute care, cancer and vascular diseases. The company has diversified revenues from sales of its own marketed products and from royalties on partnered products, and is seeking to acquire new programs and products to develop and market to specialist physicians.
For further information about BTG please visit our website at www.btgplc.com.
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com